The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global nicotine gum market size reached US$ 1.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2027, exhibiting a growth rate (CAGR) of 5.04% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Nicotine gum is an over the counter (OTC) smoking cessation product. It aims to assist individuals suffering from tobacco dependence in minimizing their consumption of cigarettes and eventually quit smoking. Nicotine is released when the gum is chewed and is absorbed into the bloodstream through the lining of the mouth. This aids in gradually curbing nicotine cravings and reducing the withdrawal symptoms and urge to smoke. It is commonly available in three variants: 2mg, 4mg and 6mg based on the nicotine content and is used by the individuals based on the number of cigarettes consumed by them on a daily basis.
The rising instances of lung cancer and other respiratory disorders is one of the key factors driving the growth of the market. Smoking is known to cause various chronic diseases, such as coronary heart disease (CHD), stroke, oropharyngeal cancer, esophageal cancer, tuberculosis, rheumatoid arthritis and various immunity-related ailments. The rising awareness regarding these ailments, along with the increasing health consciousness, is contributing to the market growth. Additionally, widespread adoption of smoking cessation therapies is acting as another growth-inducing factor. Various government and non-government organizations (NGOs) across both the developed and emerging nations are promoting the usage of smoking cessation products, such as nicotine gums, to assist individuals, especially the youth, with tobacco addiction. Other factors, including various product innovations such as the development of nicotine lozenges, rapid urbanization and extensive research and development activities, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global nicotine gum market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application and distribution channel.
Breakup by Type:
Breakup by Application:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Application, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer and Takeda Pharmaceutical Company|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at